Overview

* AtriCure ( ATRC ) Q2 revenue rises 17.1% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats estimates, improving to a loss of $0.02

* Adjusted EBITDA increases significantly, surpassing analyst forecasts, per LSEG data

Outlook

* AtriCure ( ATRC ) projects full-year 2025 revenue between $527 mln and $533 mln

* Company expects full-year 2025 adjusted EBITDA of $49 mln to $52 mln

* AtriCure ( ATRC ) anticipates full-year 2025 adjusted loss per share of $0.34 to $0.39

* Company expects modest cash flow generation for full-year 2025

Result Drivers

* PRODUCT ADOPTION - Revenue growth driven by increased adoption of AtriCure's ( ATRC ) Afib, LAA management, and post-operative pain management products

* KEY PRODUCT LINES - U.S. revenue boosted by sales of AtriClip FLEX·Mini, EnCompass clamp, and cryoSPHERE MAX probe

* INTERNATIONAL GROWTH - Significant international revenue increase across all franchises and geographic regions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $136.10 $130.20

Revenue mln mln (9

Analysts

)

Q2 Beat -$0.02 -$0.17

Adjusted (9

EPS Analysts

)

Q2 Beat $15.40 $10.10

Adjusted mln mln (7

EBITDA Analysts

)

Q2 Gross 74.5%

Margin

Q2 Gross $101.50

Profit mln

Q2 -$6.20

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for AtriCure Inc ( ATRC ) is $50.50, about 34.2% above its July 28 closing price of $33.22

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)